Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors

Prostate

Volumn 72, Issue 8, 2012, Pages 875-885

  Thomas, Christian ^a,b   Wafa, Latif A ^a   Lamoureux, Francois ^a   Cheng, Helen ^a   Fazli, Ladan ^a   Gleave, Martin E ^a   Rennie, Paul S ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

androgen receptor; bicalutamide; carbidopa; L dopa decarboxylase; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; CARBIDOPA; PROSTATE SPECIFIC ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP; CELL VIABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ADENOCARCINOMA; ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBIDOPA; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE PROGRESSION; DOPAMINE AGENTS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MALE; MICE; MICE, NUDE; NITRILES; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TOSYL COMPOUNDS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859632358     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21490     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward EM,. Cancer facts and figures 2010. Atlanta: American Cancer Society; 2010.
2. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P,. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: Data from CaPSURE™. Urol Oncol 2006; 24: 396-402. (Pubitemid 44311554)
3. Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ,. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: Long-term results. J Urol 2004; 172: 910-914. (Pubitemid 39096421)
4. Moreau JP, Delavault P, Blumberg J,. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy. Clin Ther 2006; 28: 1485-1508. (Pubitemid 44841984)
5. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80. (Pubitemid 350166735)
6. Knudsen K, Scher H,. Starving the addiction: New opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res 2009; 15: 4792-4798.
7. Koupparis A, Casey R, Robinson M, Gleave ME,. Novel targeted agents on the horizon for castration-resistant prostate cancer. Future Oncol 2010; 6: 1883-1895.
8. Zhu MY, Juorio AV,. Aromatic L-amino acid decarboxylase: Biological characterization and functional role. Gen Pharmacol 1995; 26: 681-696.
9. Wafa LA, Palmer J, Fayli L, Hurtado-Coll A, Bell RH, Nelson CC, Gleave ME, Cox ME, Rennie PS,. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors. Hum Pathol 2007; 38: 161-170. (Pubitemid 44880212)
10. Avergis M, Koutalellis G, Fragoulis EG, Scorilas A,. Expression analysis and clinical utility of L-Dopa decarboxylase (DDC) in prostate cancer. Clin Biochem 2008; 41: 1140-1149.
11. Wafa LA, Cheng H, Rao MA, Nelson CC, Cox M, Hirst M, Sadowski I, Rennie PS,. Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using repressed transactivator yeast two-hybrid system. Biochem J 2003; 375: 373-383. (Pubitemid 37315445)
12. Marsden CD, Barry PE, Parkes JD, Zilkha KJ,. Treatment of Parkinson's disease with leovdopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase. J Neurol Nuerosurg Psychiatry 1973; 36: 10-14.
13. Marsden CD, Parkes JD, Rees JE,. A year's comparison of treatment of patients with Parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet 1973; 2: 1459-1462.
14. Critchley E,. L-dopa and carbidopa (sinemet) in the management of parkinsonism. Postgrad Med J 1975; 51: 619-621.
15. Wafa LA, Cheng H, Plaa N, Ghaidi F, Fukumoto T, Fazli L, Gleave ME, Cox ME, Rennie PS,. Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression. Int J Cancer 2011; DOI: 10.1002/ijc.26287: [PMID: 21780103].
16. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M,. bicalutamide for advanced prostate cancer: The natural versus treated history of disease. J Clin Oncol 1997; 15: 2928-2938. (Pubitemid 27330021)
17. Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ,. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy. J Urol 1998; 159: 149-153. (Pubitemid 27525592)
18. Kucuk O, Fisher E, Moinpour CM, Coleman D, Hussain MH, Sartor AO, Chatta GS, Lowe BA, Eisenberger mA, Crawford ED,. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: A Southwest Oncology Group Study (SWOG 9235). Urology 2001; 58: 53-58. (Pubitemid 32633935)
19. Attard G, Reid AH, A'Hern R, Parker C, Oommen NB, Fokerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS,. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 23: 3742-3748.
20. Scher HI, Beer TM, Higano CS, Anand A, Talpin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris JM, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL,. Antitumour activity of MDV 3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010; 375: 1437-1446.
21. Leung SY, Jackson J, Miyake H, Burt H, Gleave ME,. Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors. Prostate 2000; 44: 156-163. (Pubitemid 30419190)
22. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
23. Elhaji YA, Wu JH, Gottlieb B, Betel LK, Alvarado C, Batist G, Trifiro MA,. An examination of how different mutations at arginine 855 of the androgen receptor result in different androgen insensitivity phenotypes. Mol Endocrinol 2004; 18: 1876-1886. (Pubitemid 39022609)
24. Lumbroso S, Wagschal A, Bourguet W, Georget V, Mazen I, Servant N, Audran F, Sultan C, Auzou G,. A new mutation of the androgen receptor, P817A, causing partial androgen insensitivity syndrome: In vitro an structural analysis. J Mol Endocrinol 2004; 32: 679-687. (Pubitemid 38877681)
25. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vesella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to anti-androgen therapy. Nat Med 2004; 10: 33-39. (Pubitemid 38524696)
26. Chen Y, Sawyers CL, Scher HI,. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008; 8: 440-448.
27. Chen Y, Clegg NJ, Scher HI,. Anti-androgens and androgen depleting therapies in prostate cancer: New agents for an established target. Lancet Oncol 2009; 10: 981-991.
28. Zhang W, Zhu J, Efferson CL, Ware C, Tammam J, Agagaw M, Laskey J, Bettano KA, Kasibhatla S, Reilly JF, Sur C, Majumder PK,. Inhibition of tumor growth progression by anti-androgens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res 2009; 69: 7466-7472.
29. Shanmugam R, Kusumanchi P, Cheng L, Crooks P, Neelakantan S, Matthews W, Naksharti H, Sweeney CL,. A water-soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFkappa B and generating reactive oxygen species. Prostate 2010; 70: 1074-1086.
30. Kolvenbag GJ, Blackledge GR,. Worldwide activity and safety of bicalutamide: A summary review. Urology 1996; 47: 70-79. (Pubitemid 126691289)
31. Tyrell CJ, Iversen P, Tammela T, Anderson J, Bjoerk T, Kaisary AV, Morris T,. Tolerability, efficacy and pharmacokinetics of bicalutamide 300mg, 450mg and 600mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration. Urology 2006; 98: 563-572. (Pubitemid 44185877)
32. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G,. Maximal androgen blockade for patients with metastatic prostate cancer: Outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Urology 1996; 47: 54-60. (Pubitemid 126691287)
33. Lodde M, Lacombe L, Fradet Y,. Salvage therapy with bicalutamide 150mg in nonmetastatic castration-resistant prostate cancer. Urology 2010; 76: 1189-1193.
34. Cheng L, Bergstralh EJ, Cheville JC, Slezak J, Corica FA, Zincke H, Blute ML, Bostwick DG,. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 1998; 22: 1491-1500. (Pubitemid 28550644)
35. Rathkopf D, Liu G, Carducci M,. Phase I dose-escalation study of the novel anti-androgen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res 2011; 17 (4): 880-887.
36. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Schmith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL,. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790.
37. Foster WR, Car BD, Shi H, Levesque PC, Obermeier MT, Gan J, Arezzo JC, Powlin SS, Dinchuk JE, Balog A, Salvati ME, Attar RM, Gottardis MM,. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011; 71: 480-488.